US5990100AExpiredUtility

Composition and method for treatment of psoriasis

87
Assignee: PANDA PHARMACEUTICALS L L CPriority: Mar 24, 1998Filed: Aug 28, 1998Granted: Nov 23, 1999
Est. expiryMar 24, 2018(expired)· nominal 20-yr term from priority
Inventors:E. William RosenbergThomas M. GlennRobert B. Skinner, Jr.Patricia W. Noah
A61K 31/573A61K 31/07A61K 9/0014A61K 31/22A61K 35/04A61K 31/23A61K 47/26A61K 47/10A61K 31/57A61K 47/20A61K 31/575
87
PatentIndex Score
139
Cited by
25
References
36
Claims

Abstract

Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A pharmaceutical composition for use in the treatment of psoriasis comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human. 
     
     
       2. A composition according to claim 1, said composition being at least 25 weight percent isopropyl myristate. 
     
     
       3. A composition according to claim 2, said composition being at least 40 weight percent isopropyl myristate. 
     
     
       4. A composition according to claim 2, said composition being 38-60 weight percent isopropyl myristate. 
     
     
       5. A composition according to claim 1, said composition being at least 38 weight percent isopropyl myristate, at least 40 weight percent of said composition being formed from water, ethanol, isopropyl alcohol, or any combination thereof. 
     
     
       6. A composition according to claim 1, said composition being 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol. 
     
     
       7. A method of treating psoriasis comprising topically administering to a human having psoriasis a pharmaceutical composition comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human. 
     
     
       8. A composition according to claim 1, said composition comprising 0.001-5 weight percent corticosteroid. 
     
     
       9. A composition according to claim 8, wherein said composition is at least 25 weight percent isopropyl myristate. 
     
     
       10. A composition according to claim 9, wherein said composition is at least 35 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       11. A composition according to claim 10, wherein said alcohol is ethanol, isopropyl alcohol, or a mixture thereof. 
     
     
       12. A composition according to claim 11, said composition being 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol. 
     
     
       13. A composition according to claim 1, wherein said component (a) anti-psoriatic agent is present at 0.005 to 10 weight percent. 
     
     
       14. A composition according to claim 1, wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       15. A composition according to claim 1, said composition comprising 0.0001-0.1 weight percent calcipotriol. 
     
     
       16. A composition according to claim 15, wherein said composition is at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       17. A composition according to claim 1, said composition comprising 0.001-5 weight percent of a corticosteroid other than hydrocortisone. 
     
     
       18. A composition according to claim 17, wherein said composition is at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       19. A composition according to claim 1, wherein at least 40 weight percent of said composition is formed from water, ethanol, isopropyl alcohol, or any combination thereof. 
     
     
       20. A composition according to claim 1, said composition being 30-55 weight percent isopropyl myristate. 
     
     
       21. A composition according to claim 1, said composition consisting essentially of said anti-psoriatic agent, said isopropyl myristate, and at least 40 weight percent water, alcohol or a mixture of water and alcohol. 
     
     
       22. A composition according to claim 21, wherein said anti-psoriatic agent is a corticosteroid other than hydrocortisone. 
     
     
       23. A composition according to claim 21, wherein said anti-psoriatic agent is calcipotriol. 
     
     
       24. A composition according to claim 1, said composition consisting of said anti-psoriatic agent, said isopropyl myristate, surfactant, and at least 40 weight percent of a mixture of water and alcohol. 
     
     
       25. A composition according to claim 24, wherein said anti-psoriatic agent is a corticosteroid other than hydrocortisone. 
     
     
       26. A method according to claim 7, wherein said composition is at least 25 weight percent isopropyl myristate. 
     
     
       27. A method according to claim 7, wherein said composition is at least 40 weight percent isopropyl myristate. 
     
     
       28. A method according to claim 7, wherein said composition is 30-60 weight percent isopropyl myristate. 
     
     
       29. A method according to claim 7, wherein said composition is at least 38 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, ethanol, isopropyl alcohol, or any combination thereof. 
     
     
       30. A method according to claim 7, wherein said composition comprises 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol. 
     
     
       31. A method according to claim 7, wherein said composition comprises 0.001-5 weight percent corticosteroid and at least 35 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       32. A method according to claim 7, wherein said composition comprises 0.0001-0.1 weight percent calcipotriol and at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       33. A method according to claim 7, wherein said composition comprises 0.001-5 weight percent of a corticosteroid other than hydrocortisone, wherein said composition comprises at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       34. A method according to claim 7, wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof. 
     
     
       35. A method according to claim 7, wherein said composition consists essentially of said anti-psoriatic agent, said isopropyl myristate, and at least 40 percent water, alcohol, or a mixture of water and alcohol. 
     
     
       36. A method according to claim 35, wherein said anti-psoriatic agent is calcipotriol or a corticosteroid other than hydrocortisone.

Join the waitlist — get patent alerts

Track US5990100A — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.